Training Experience Required
- Basic knowledge in onco-immunology
- A previous research experience would be a plus
- Knowledge in bioinformatics would be a plus
Institut Curie dates back to 1909, when Marie Curie implemented in the heart of Paris her bench-to-bedside vision of a research-care continuum. A leading player in the fight against cancer, the internationally renowned Institut Curie combines a Research Center and a Hospital Group that provides care for all types of cancers - including the rarest forms.
By embracing a crossdisciplinary approach, researchers and physicians develop together cancer-focused basic, translational and clinical research to discover more effective treatments and improve care for patients.
The Center for Cancer immunotherapy of Institut Curie, launched in 2018, accommodates basic research and translational research laboratories, consultation rooms and hospital beds on a dedicated hospital floor. Its objectives are to understand resistance to immunotherapies and to develop innovative anti-cancer treatments building on the multidisciplinary strengths of Institut Curie in immunology, epigenetics, cellular biology, and medical oncology.
The Center for Cancer immunotherapy is currently implementing 11 clinical trials in immunotherapy (including observational studies, biomarker validation trials, specific focus on neoadjuvant setting, combination therapies with anti-checkpoint inhibitors) in uveal melanoma, breast, gynecological, H&N, prostate and pediatric cancers.
The main axes covered by the Center for Cancer immunotherapy research teams are:
Early discovery: Understanding of tumor biology and its cross-talk with the host immune system.
- Antigen presentation in dendritic cells
- The mechanisms underlying human T cell activation
- Adaptive immunity in inflammation, cancer and infectious diseases
Translational immunology: Transferring basic knowledge to clinical applications
- Prognostic/predictive biomarkers of response and toxicity associated to immunotherapies
- Predictive transcriptomic signatures
- Target discovery in immuno-oncology
- In vitro/preclinical target validation
- Drug design (Antibodies, CAR-T, long peptides / DNA vaccines)
Early-phase trials in Immuno-oncology: Promoting and implementing early-phase clinical trials
- Augment the number of trials in immunotherapy (Phase I to III) at Institut Curie
- Enlarge the number of indications treated with immunotherapies by better defining the niche of patients susceptible to respond
- Launching investigator driven clinical trials
In a very stimulating environment the fellow will benefit from top-of-the-art shared technological platforms (including NGS, preclinical investigation lab, experimental pathology and cytometry).
At least 3 of the Center PIs are interested in hosting ESMO fellows, including Emanuela Romano, Olivier Lantz and Eliane Piaggio.